期刊文献+

巨大囊性嗜铬细胞瘤/副神经节瘤诊治研究进展 被引量:1

Research progress on diagnosis and treatment of giant cystic pheochromocytoma/paraganglioma
原文传递
导出
摘要 嗜铬细胞瘤并不常见,而巨大囊性嗜铬细胞瘤更为少见,是嗜铬细胞瘤的一个亚组,大部分因为肿瘤坏死和出血过程形成囊性,极少为真囊肿。因为大部分儿茶酚胺在肿瘤内代谢或储存,当肿瘤发生囊性退变时,儿茶酚胺生成减少或储存在胞膜下,不易释放入血,导致其缺乏典型嗜铬细胞瘤的常见症状,生化检查儿茶酚胺代谢产物阴性亦不少见,加之影像学表现多样,不易与其他腹腔或腹膜后占位鉴别,早期诊断极困难。本文就巨大囊性嗜铬细胞瘤的发生机制、临床表现、诊治等方面综述其进展,以加深对本病的认识,提高临床诊断的准确率。 Pheochromocytoma is not common,while giant cystic pheochromocytoma is even more rare.It is a subgroup of pheochromocytoma.Most of them are cystic due to tumor necrosis and hemorrhagic process,and rarely are true cysts.Because most of the catecholamines are metabolized or stored in the tumor,when the tumor undergoes cystic degeneration,the production of catecholamines is reduced or stored under the cell membrane,which is not easy to release into the blood,resulting in a lack of common symptoms of typical pheochromocytoma.Biochemical examination of catecholamines metabolites is more likely to be negative.In addition to the diverse imaging findings,it is not easy to differentiate from other abdominal or retroperitoneal space,and early diagnosis is extremely difficult.This article reviews the progress of giant cystic pheochromocytoma in terms of its mechanism,clinical manifestations,diagnosis and treatment,in order to deepen the understanding of the disease and improve the accuracy of clinical diagnosis.
作者 张越 周波 Zhang Yue;Zhou Bo(Department of Endocrinology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
出处 《国际内分泌代谢杂志》 2021年第3期212-215,共4页 International Journal of Endocrinology and Metabolism
关键词 嗜铬细胞瘤 副神经节瘤 囊肿 诊治 Pheochromocytoma Paraganglioma Cyst Diagnosis and treatment
  • 相关文献

参考文献3

二级参考文献24

  • 1Remine WH, Chong GC, Van Heerden JA, et al. Current man- agement of pheochromocytoma [ J ]. Ann Surg, 1974, 179 ( 5 ) : 740-748.
  • 2Hescot S, Leboulleux S, Amar L, et al. One-year progression- free survival of therapy-naive patients with malignant pheochromo- cytoma and paraganglioma[ J]. J Clin Endocrinol Metab, 2013, 98 (10) :4006-4012. DOI : 10. 1210/jc. 2013-1907.
  • 3Sisson JC, Shapiro B, Beierwaltes WH, et al. Radiopharmaceu- tical treatment of malignant pheochromocytoma[ J ]. J Nuel Med, 1984,25 (2) : 197-206.
  • 4Rutherford MA, Rankin A J, Yates TM, et al. Management of metastatic phaeochromocytoma and paraganglioma : use of" iodine- 131-meta-iodobenzylguanidine therapy in a tertiary referral centre [J]. QJM, 2015, 108 ( 5 ) : 361-368. DOI: 10. 1093/qjmed/ hcu208.
  • 5van Hulsteijn LT, Niemeijer ND, Dekkers OM,et al. (131) I- MIBG therapy for malignant paraganglioma and phaeochromocyto- ma: systematic review and meta-analysis ~ J ]. Clin Endocrinol (Oxf) ,2014,80(4) :487-501. DOI: 10. llll/cen, 12341.
  • 6Gedik GK, Hoefnagel CA, Bais E,et al. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma [ J ]. Eur J Nucl Med Mol Imaging,2008,35 (4) : 725-733.
  • 7Loh KC, Fitzgerald PA, Matthay KK, et al. The treatment of ma- lignant pheochromocytoma with iodine-131 metaiodobenzylguani- dine (131I-MIBG) : a comprehensive review of 116 reported pa- tients[ J]. J Endocrinol Invest, 1997,20 ( 11 ) :648-658.
  • 8Gonias S, Goldsby R, Matthay KK, et al. Phase U study of high-dose [ 131 I ] metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma [ J ]. J Clin Oncol, 2009,27 (25) :4162-4168. DOI : 10. 1200/JCO. 2008. 21. 3496.
  • 9Shilkrut M, Bar-Deroma R, Bar-Sela G,et al. Low-dose iodine- 131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience [J]. Am J Clin Oncol, 2010,33 ( 1 ) :79-82. DOI: 10. 1097/ COC. 0bO13e31819e2c28.
  • 10Sze WC, Grossman AB, Goddard I, et al. Sequelae and survivor- ship in patients treated with ( 131 ) I-MIBG therapy [ J]. Br J Cancer, 2013,109 (3) :565-572. DOI : 10. 1038/hjc. 2013. 365.

共引文献16

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部